DexCom

Stories

Landmark trial shows continuous glucose monitors cut A1c in type 2 diabetes patients not on insulin

Manufacturer of the Dexcom G7 CGM used in the CONNECT trial; expects a CMS coverage decision before end of 2026 and implementation in mid-2027

For millions of Americans with type 2 diabetes who don't take insulin, checking blood sugar has meant fingerstick tests a few times a day. A 26-week trial published in the New England Journal of Medicine in October showed that continuous glucose monitors (CGMs), small sensors worn on the arm that stream glucose readings, kept patients in a healthy blood sugar range for about five extra hours each day.

Updated Oct 18